ClinicaliQ Trial Snapshot
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Active Not Recruiting • Phase III • NCT04680052.
- Adding tafasitamab to standard lymphoma treatment improves outcomes in patients with relapsed or refractory follicular or marginal zone lymphoma.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL. Conditions: Follicular Lymphoma, Marginal Zone Lymphoma Interventions: tafasitamab, rituximab, lenalidomide, placebo Lead Sponsor: Incyte Corporation Planned Enrollment: 654 participants